Leerink Partners Assumes Equillium at Outperform, Announces Price Target of $6
Leerink Partners analyst Will Soghikian assumes Equillium (NASDAQ:EQ) with a Outperform rating and announces Price Target of $6.
Stocks · News reference
Australia's Therapeutic Goods Administration Grants Equillium Human Research Ethics Committee Approval For Phase 1 Clinical Trial Of EQ504.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Equillium, Inc. (EQ)
Filed: 2026-10-05 AccNo: 0001193125-26-414364 Size: 145 KB Item 8.01: Other Events
Roth Capital Reiterates Buy on Equillium, Maintains $12 Price Target
Roth Capital analyst Adam Walsh reiterates Equillium (NASDAQ:EQ) with a Buy and maintains $12 price target.